CALCA and autoimmune hepatitis: A case series has shown the presence of inflammatory complications in patients receiving CGRP inhibitors, such as autoimmune hepatitis, Susac syndrome, DRESS syndrome, Weber syndrome, severe polyarthralgia, exacerbation of psoriasis, and urticarial eczema, after 1–16 months of treatment [11].